ingenol mebutate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4226 75567-37-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • picato
  • PEP005
  • Ingenol 3-angelate
  • 3-Angeloylingenol
  • 3-Ingenyl angelate
  • ingenol mebutate
protein kinase C agonist and antineoplastic
  • Molecular weight: 430.54
  • Formula: C25H34O6
  • CLOGP: 3.41
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 104.06
  • ALOGS: -3.19
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 23, 2012 FDA LEO PHARMA AS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site vesicles 923.91 129.39 109 284 315 2357377
Application site erythema 794.96 129.39 108 285 1172 2356520
Incorrect product administration duration 591.15 129.39 91 302 2404 2355288
Application site pain 563.34 129.39 82 311 1444 2356248
Product administered at inappropriate site 329.48 129.39 47 346 676 2357016
Application site swelling 279.32 129.39 36 357 222 2357470
Application site scab 261.08 129.39 30 363 53 2357639
Application site exfoliation 209.38 129.39 26 367 111 2357581
Application site discharge 147.83 129.39 18 375 62 2357630
Application site reaction 145.22 129.39 21 372 322 2357370

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site erythema 360.35 330.57 50 198 584 1745949

Pharmacologic Action:

SourceCodeDescription
ATC D06BX02 DERMATOLOGICALS
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
CHEMOTHERAPEUTICS FOR TOPICAL USE
Other chemotherapeutics
CHEBI has role CHEBI:35610 antineoplastic agent
FDA EPC N0000184015 Cell Death Inducer
FDA PE N0000009176 Increased Cellular Death

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Actinic keratosis indication 201101007 DOID:8866

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.14 acidic
pKa2 11.74 acidic
pKa3 13.75 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.015% PICATO LEO LABS N202833 Jan. 23, 2012 RX GEL TOPICAL 7410656 Oct. 10, 2020 TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS
0.05% PICATO LEO LABS N202833 Jan. 23, 2012 RX GEL TOPICAL 7410656 Oct. 10, 2020 TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS
0.015% PICATO LEO LABS N202833 Jan. 23, 2012 RX GEL TOPICAL 8536163 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.015% PICATO LEO LABS N202833 Jan. 23, 2012 RX GEL TOPICAL 8716271 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.015% PICATO LEO LABS N202833 Jan. 23, 2012 RX GEL TOPICAL 8735375 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.015% PICATO LEO LABS N202833 Jan. 23, 2012 RX GEL TOPICAL 9820959 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.015% PICATO LEO LABS N202833 Jan. 23, 2012 RX GEL TOPICAL 9861603 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.05% PICATO LEO LABS N202833 Jan. 23, 2012 RX GEL TOPICAL 8536163 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.05% PICATO LEO LABS N202833 Jan. 23, 2012 RX GEL TOPICAL 8716271 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.05% PICATO LEO LABS N202833 Jan. 23, 2012 RX GEL TOPICAL 8735375 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.05% PICATO LEO LABS N202833 Jan. 23, 2012 RX GEL TOPICAL 9820959 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.05% PICATO LEO LABS N202833 Jan. 23, 2012 RX GEL TOPICAL 9861603 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.015% PICATO LEO LABS N202833 Jan. 23, 2012 RX GEL TOPICAL 9789078 May 15, 2033 TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP USING MORE THAN ONE TREATMENT COURSE OF INGENOL MEBUTATE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Protein kinase C delta type Kinase ACTIVATOR EC50 8.33 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Protein kinase C alpha type Kinase EC50 6.20 SCIENTIFIC LITERATURE
Protein kinase C beta type Kinase EC50 6.84 SCIENTIFIC LITERATURE
Protein kinase C epsilon type Kinase EC50 8.96 SCIENTIFIC LITERATURE
Serine/threonine-protein kinase D1 Kinase EC50 7.52 SCIENTIFIC LITERATURE
Protein kinase C gamma type Kinase ACTIVATOR Ki 9.79 IUPHAR

External reference:

IDSource
C3257744 UMLSCUI
D09393 KEGG_DRUG
7686S50JAH UNII
9006 INN_ID
715552008 SNOMEDCT_US
1242806 RXNORM
014146 NDDF
28281 MMSL
4031407 VANDF
710279008 SNOMEDCT_US
6918670 PUBCHEM_CID
CHEBI:66913 CHEBI
30220-46-3 SECONDARY_CAS_RN
C486592 MESH_SUPPLEMENTAL_RECORD_UI
DB05013 DRUGBANK_ID
CHEMBL1863513 ChEMBL_ID
CHEMBL2165402 ChEMBL_ID
7443 IUPHAR_LIGAND_ID
C008125 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Picato HUMAN PRESCRIPTION DRUG LABEL 1 50222-502 GEL 150 ug TOPICAL NDA 18 sections
Picato HUMAN PRESCRIPTION DRUG LABEL 1 50222-503 GEL 500 ug TOPICAL NDA 18 sections